Table 3.

Strategies for consideration in “salvage” immune tolerance induction (ITI) therapies.

  • Switch to high-dose factor VIII (FVIII) schedule (200 units/kg/day)

  • Switch to von Willebrand factor containing plasma-derived FVIII concentrate

  • Immunoadsorption + immunosuppression

  • Rituximab

 

  • Switch to high-dose factor VIII (FVIII) schedule (200 units/kg/day)

  • Switch to von Willebrand factor containing plasma-derived FVIII concentrate

  • Immunoadsorption + immunosuppression

  • Rituximab

 
View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal